NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-11-03 11:34இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Laurus Labs Q2 FY27 Earnings Call: CDMO Up 86% YoY to Rs 875 Cr; Revenue Reaches Rs 2,206 Cr
Laurus Labs hosted its Q2 FY27 earnings conference call, detailing a record quarterly revenue of Rs 2,206 crore and an EBITDA margin of 34.5% (up 2.7 percentage points). Small molecule CDMO revenue surged 86% year-on-year to Rs 875 crore, while Affordable Medicines grew 15% to Rs 1,302 crore. The company commissioned a commercial peptide manufacturing block with over 16,000 liters of solid-phase peptide synthesis capacity, while small molecule API reactor volume reached over 9,000 kiloliters. Strategic initiatives include acquiring a 60% stake in Galenvs Sciences and a majority stake in SI & C Resins to support peptide and oligo CDMO expansion.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs published the detailed transcript of its Q2 FY27 earnings call held on October 29, 2026.
ஏன் இது முக்கியம்Demonstrates strong execution in high-margin CDMO offerings and strategic moves into peptides and oligonucleotides, bolstering margin profile and medium-term growth visibility.
Q2 FY27 Total Revenue: INR 2,206 கோடிQ2 CDMO Revenue: INR 875 கோடிEBITDA லாப வரம்பு: 34.5%Small Molecule API Reactor Volume: over 9,000 kilolitersPeptide Synthesis Reactor Volume: over 16,000 liters
📅 குறுகிய காலம்Earnings transcript provides confirmation of strong Q2 execution, CDMO acceleration, and stable pricing in formulations.
📈 நீண்ட காலம்Expansion into complex modalities like peptides and oligonucleotides, along with the operationalization of Laurus Bio 4, supports long-term CDMO mix improvement and margin sustainability.
⚠ அபாய எச்சரிக்கைகள்
Laurus Bio reported quarterly sales of only Rs 29 crore with H1 losses, pending the commissioning of Bio 4
Execution and ramp-up risks associated with complex peptide validation batches and heavy ongoing capex suppressing asset turns
👀 கவனிக்க வேண்டியவை
Track the commercial ramp-up of the newly commissioned peptide block and the operational start of the Laurus Bio 4 fermentation facility targeted by end-2026.
Q2 FY27 Net Profit Jumps 126% to ₹441 Cr; To Acquire 60% Stake in Galenvs Sciences
Laurus Labs delivered a strong Q2 FY27 performance with revenue growing 33% YoY to ₹2,206 crore and net profit surging 126% YoY to ₹441 crore, driven by a 75% surge in CDMO division revenue (₹904 crore). EBITDA margin expanded 850 bps YoY to 34.5%, aided by operational leverage and gross margin improvement to 63.0%. Alongside earnings, the company announced two strategic acquisitions: acquiring a 60% stake in Canada-based Galenvs Sciences (oligonucleotides) and a 52% stake in SI&C Resins (peptide-resins). The board also declared an interim dividend of ₹1.00 per share.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs posted record Q2 FY27 financial results alongside signing definitive agreements to acquire a 60% stake in Galenvs Sciences and a 52% stake in SI&C Resins.
ஏன் இது முக்கியம்The performance highlights a structural shift toward high-margin CDMO small molecules, lifting operating margins from 26% to 34.5%, while the acquisitions expand capabilities into next-generation oligonucleotide and peptide therapeutics.
📅 குறுகிய காலம்Positive sentiment is expected following an earnings beat with 126% PAT growth and strong EBITDA margin expansion, coupled with expansionary strategic M&A announcements.
📈 நீண்ட காலம்Strategic scale-up in CDMO, combined with new capabilities in peptides (SPPS >16,000L capacity) and oligonucleotides, positions Laurus well to transition from generic APIs to high-value innovator biopharma services.
⚠ அபாய எச்சரிக்கைகள்
Deal values for Galenvs Sciences and SI&C Resins acquisitions are not disclosed in the press release
Bio business experienced quarterly contraction (-38% YoY to ₹29 Cr) due to campaign phasing
High capital expenditure intensity (capex at 20% of revenue) raises execution and asset turn risks
👀 கவனிக்க வேண்டியவை
Track the integration timeline and regulatory approvals for the Galenvs Sciences acquisition, alongside commercial ramp-up of the newly operational peptide plant (>16,000L SPPS capacity) and the LB-4 fermentation unit commissioning in Q3 FY27.
Laurus Labs H1 Revenue Rises 31% to ₹4,233 Cr; Plans >₹3,000 Cr Capex and 2 CDMO Acquisitions
Laurus Labs reported strong H1 FY27 performance with revenue growing 31% year-on-year to ₹4,233 crore and EBITDA reaching ₹1,406 crore (33.2% margin, up 7.8 percentage points). The company announced definitive agreements to acquire a 60% stake in Galenvs (oligonucleotides) and 52% in SI&C Resins (peptides solid support) to strengthen its integrated CDMO platform. Capital expenditure for H1 stood at ₹864 crore (20% of revenue), and the management outlined plans to invest >₹3,000 crore over FY27-FY28 (representing ~41% of TTM revenue).
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs released its Q2/H1 FY27 earnings presentation, highlighting a sharp operational margin rebound and strategic acquisitions in Oligos and Peptides.
ஏன் இது முக்கியம்The shift toward high-margin CDMO programs, peptides, and ADCs is driving gross margin expansion to 62.9% and EBITDA margin to 33.2%, backed by heavy capex of >₹3,000 crore.
📅 குறுகிய காலம்Earnings call commentary and strong H1 operating leverage (33.2% EBITDA margin) provide positive momentum for near-term sentiment.
📈 நீண்ட காலம்Large-scale capex (>₹3,000 Cr over FY27-FY28) in high-growth modalities like Peptides, ADCs, and Oligonucleotides structurally positions Laurus as a fully integrated global CDMO player.
⚠ அபாய எச்சரிக்கைகள்
High capital intensity with planned capex exceeding ₹3,000 crore
Integration and regulatory execution risks in new advanced modalities (ADCs and Oligos)
👀 கவனிக்க வேண்டியவை
Track the integration timeline and deal completion of Galenvs and SI&C Resins, alongside the commercial ramp-up of the Gene Therapy & ADC facilities scheduled by end-2027.
Laurus Labs Declares ₹1.00 Interim Dividend for FY27; Sets Record Date as Nov 6, 2026
Laurus Labs has declared an interim dividend of ₹1.00 per equity share of face value ₹2.00 each (50%) for FY 2026-27. The company has fixed November 6, 2026, as the record date to determine eligible shareholders. The dividend payout is scheduled to take place on or after November 19, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs has declared an interim dividend payout of ₹1.00 per equity share for FY 2026-27.
ஏன் இது முக்கியம்Represents routine capital return to shareholders, supported by ongoing profitability (TTM PAT of ₹1,090 Cr).
Interim Dividend per share: Re. 1.00/-Dividend percentage: 50%ஒரு பங்கின் முக மதிப்பு: Rs.2/-ரெக்கார்ட் தேதி: நவம்பர் 6, 2026Payment Date: on or after November 19, 2026
📅 குறுகிய காலம்Shareholders holding stock before the ex-date ahead of November 6, 2026, will be eligible for the ₹1.00 per share payout.
📈 நீண்ட காலம்Limited; this is a standard interim dividend distribution consistent with regular corporate actions.
👀 கவனிக்க வேண்டியவை
Track the ex-dividend date prior to November 6, 2026, to determine dividend entitlement, and observe full Q2 FY27 earnings disclosures for overall operational performance.
Laurus Labs to Acquire 52% Stake in SI&C Resins for ₹32.50 Cr to Expand Peptide Supply Chain
Laurus Labs' Board has approved the acquisition of a 52% equity stake in Hyderabad-based SI & C Resins Private Limited (SI&C) for a primary investment of ₹32.50 crore. The deal values SI&C at a pre-money valuation of ₹30 crore, with an option to invest an additional ₹30 crore as funding needs arise. SI&C specializes in polymer and silica-based products for peptide synthesis and chromatography gels, which will make Laurus's peptide manufacturing capabilities fully integrated. Financially, the acquisition is minor relative to Laurus's ₹1,17,351 crore market cap and ₹7,270 crore TTM revenue, representing a strategic niche bolt-on.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs has entered into an agreement to acquire majority control (52%) of SI & C Resins Pvt Ltd via primary share subscription.
ஏன் இது முக்கியம்Provides backwards integration for Laurus Labs' peptide synthesis and chromatography purification offerings, strengthening its high-margin CDMO capabilities.
📅 குறுகிய காலம்Neutral to mildly positive; transaction size is small and will not materially impact near-term consolidated earnings.
📈 நீண்ட காலம்Strategically positive as it secures critical peptide raw material technology (SPPS supports and resins), supporting long-term expansion in the CDMO peptide space.
⚠ அபாய எச்சரிக்கைகள்
Execution risk related to transferring partnership assets and scaling SI&C's manufacturing plant from early-stage operations
👀 கவனிக்க வேண்டியவை
Track the closing of the transaction and the timeline for SI&C's planned large-scale manufacturing plant for peptide resins.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Laurus Labs Invests ₹107.8 Cr in KRKA Pharma JV via Rights Issue; Stake Remains 49%
Laurus Labs has infused ₹107.8 crore (INR 1,078,000,000) into its joint venture, KRKA Pharma Private Limited, via a rights issue. The company acquired 107,800,000 equity shares of KRKA at a face value of ₹10 each. Following this investment, Laurus Labs' total holding in the JV reaches 262,150,000 equity shares, while its ownership stake remains unchanged at 49%. The capital deployment represents approximately 1.48% of Laurus Labs' TTM revenue of ₹7,270 crore and supports its ongoing market expansion strategy.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs completed a planned follow-on cash infusion of ₹107.8 crore into its joint venture, KRKA Pharma Private Limited, through a rights issue.
ஏன் இது முக்கியம்The investment supports the operational scale-up of the KRKA JV targeting new market expansion, funded comfortably within the company's financial profile.
முதலீட்டுத் தொகை: ₹107.8 கோடிShares acquired: 107,800,000Total shares held post-issue: 262,150,000Shareholding percentage: 49%Investment vs TTM Revenue: ~1.48%
📅 குறுகிய காலம்Neutral impact on stock performance as the rights issue investment was previously intimated on April 30, 2026, and involves a modest cash outflow.
📈 நீண்ட காலம்Strengthens the strategic partnership with KRKA d.d. for finished formulations and geographic market expansion, contributing to long-term diversification.
⚠ அபாய எச்சரிக்கைகள்
Execution and gestation timeline risks in JV operations before meaningful profit contribution.
👀 கவனிக்க வேண்டியவை
Monitor upcoming quarterly updates for disclosures on KRKA Pharma JV operational progress, commercial launch timelines, and revenue contribution.
Laurus Labs Outlines >₹3,000 Cr Growth Capex; Q1 FY27 PAT Jumps 126% YoY to ₹368 Cr
Laurus Labs released its September 2026 investor presentation detailing strong Q1 FY27 financial performance and future expansion plans. For Q1 FY27, revenue climbed 29% YoY to ₹2,026 Cr with net profit surging 126% YoY to ₹368 Cr, driven by high-margin CDMO ramp-ups. The company proposed >₹3,000 Cr in cumulative capex over FY27-FY28 (representing ~41% of TTM revenue of ₹7,270 Cr), following ₹4,300 Cr invested across FY22-FY26. Management is targeting sustained EBITDA margins above 30% from FY27 onward, backed by advanced therapies including ADCs, precision fermentation, and gene therapies.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs detailed its strategic roadmap, confirming >₹3,000 Cr in forward capex across FY27-FY28 and guiding for >30% EBITDA margins from FY27 onward.
ஏன் இது முக்கியம்The massive capital deployment into CDMO, ADC platforms, and fermentation aims to structurally re-rate margins and expand high-barrier technology offerings beyond legacy APIs.
📅 குறுகிய காலம்Strong operational momentum reflected in the presentation (EBITDA margin expansion to 31.8%) provides a positive catalyst for market sentiment.
📈 நீண்ட காலம்Transforming into a specialized CDMO and advanced biologics player (peptides, gene therapy, ADCs) backed by aggressive capital deployment provides substantial structural runway.
⚠ அபாய எச்சரிக்கைகள்
Execution delays in complex projects (ADC, fermentation, Unit 7)
High capital intensity with net debt / EBITDA at 1.3x
Global regulatory and USFDA inspection risks across 15 manufacturing sites
👀 கவனிக்க வேண்டியவை
Track the commercial commissioning milestones of the enzyme fermentation plant by late 2026 and Phase 1 of the Unit 7 large-scale API facility in 2027.
Laurus Labs reported a strong Q1 FY27 with revenue growing 29% YoY to ₹2,026 cr, primarily driven by a 69% surge in the CDMO segment. EBITDA margins expanded significantly to 31.8%, up 700 bps from the previous quarter, reflecting improved capacity utilization and a favorable product mix. Management has aggressively increased its FY27 capex guidance to ₹2,000 cr (approx. 29% of TTM revenue) to meet rising customer demand. Strategic advancements include a new ADC molecule agreement and the final stages of acquiring a 500-acre land parcel for future expansion.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has significantly accelerated its CDMO business and nearly doubled its annual capex guidance to support high demand for complex molecules.
ஏன் இது முக்கியம்The shift towards high-margin CDMO and complex technology platforms (ADCs, Peptides) is structurally improving the company's profitability and reducing its dependence on the volatile generics market.
📅 குறுகிய காலம்The sharp margin recovery and strong CDMO performance are likely to be viewed positively by the market in the coming weeks.
📈 நீண்ட காலம்The aggressive capacity expansion and focus on complex modalities like ADCs and gene therapy position the company for a higher growth trajectory over the next 2-3 years.
👀 கவனிக்க வேண்டியவை
Monitor the execution timeline of the ₹2,000 cr capex plan and the operationalization of the new fermentation capacity at Laurus Bio by year-end. Watch for continued margin stability above 30% as the CDMO mix increases.
126% PAT Growth: Laurus Labs Reports Strong Q1 FY27 with ₹2,026 Cr Revenue
Laurus Labs delivered a robust Q1 FY27 with revenue growing 29% YoY to ₹2,026 Cr, driven primarily by a 67% surge in the high-margin CDMO segment. Net profit jumped 126% to ₹368 Cr, while EBITDA margins expanded significantly by 700 bps to 31.8% due to better capacity utilization and segment mix. The company continues its aggressive expansion, investing 19% of sales into CAPEX and in-licensing two Antibody Drug Conjugate (ADC) assets for the Indian market.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs has successfully shifted its revenue mix toward high-margin CDMO services, which now contribute significantly to the bottom line, alongside a major margin expansion from 24.8% to 31.8%.
ஏன் இது முக்கியம்The results validate the company's transition from a generic API player to a diversified CDMO and specialty biotech firm, which typically commands higher valuations and offers more stable long-term growth.
Q1 வருவாய்: ₹2,026 கோடிYoY PAT Growth: 126%EBITDA லாப வரம்பு: 31.8%CDMO Revenue Growth: 67%Capex as % of Sales: 19%Q1 வருவாய் vs TTM வருவாய்: 29.7%
📅 குறுகிய காலம்The stock is likely to react positively to the sharp margin expansion and the significant beat in net profit compared to previous quarters.
📈 நீண்ட காலம்The structural shift towards CDMO, Biologics, and ADCs, supported by heavy ongoing CAPEX, positions the company for sustained growth over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
High CAPEX and R&D intensity may pressure short-term cash flows
👀 கவனிக்க வேண்டியவை
Monitor the commissioning of the new fermentation facility expected in Q3 FY27 and the progress of the KRKA JV production blocks scheduled for mid-2027. Investors should track the execution of the 125+ active CDMO projects as they transition to commercial stages.
Laurus Labs Q1 Net Profit Jumps 124% YoY to ₹362 Cr; Revenue Up 29%
Laurus Labs reported a strong start to FY27, with consolidated revenue growing 29.1% YoY to ₹2,026.31 Cr. Net profit more than doubled to ₹362.07 Cr from ₹161.68 Cr in the year-ago period, reflecting significant margin expansion. The company's operating efficiency improved as total expenses grew by only 14.6% despite the 29% revenue surge. This performance suggests a strong recovery and potential scale-up in high-margin segments like CDMO.
உச்சம் நம்பிக்கை
என்ன மாறியதுLaurus Labs has reported a sharp turnaround in profitability and revenue growth for Q1 FY27 compared to the relatively subdued performance in early FY26.
ஏன் இது முக்கியம்The significant jump in margins and profit suggests that the company's investments in CDMO and specialized APIs are beginning to yield higher returns, potentially re-rating the stock if sustained.
📅 குறுகிய காலம்The stock is likely to react positively in the short term due to the substantial profit beat and margin improvement over previous quarters.
📈 நீண்ட காலம்The structural shift towards CDMO and Bio-ingredients, coupled with the upcoming ADC technology platform, supports a positive long-term outlook if execution remains on track.
⚠ அபாய எச்சரிக்கைகள்
Regulatory risks from USFDA inspections
Execution delays in high-margin CDMO contracts
Pending NCLT approval for internal restructuring
👀 கவனிக்க வேண்டியவை
Monitor the execution of the CDMO segment and the timeline for the Laurus Bio capacity expansion expected by late 2026. Investors should also track the NCLT approval process for the merger of Laurus Synthesis Private Limited.
Laurus Labs to Hold 21st AGM on July 2, 2026; Proposes ₹2.00 Total Dividend Ratification
Laurus Labs has scheduled its 21st Annual General Meeting (AGM) for July 2, 2026, to be conducted via video conferencing. Shareholders will vote on the ratification of two interim dividends paid during FY 2025-26, totaling ₹2.00 per equity share. The agenda also includes the appointment of two new Independent Directors, Dr. Shekhar Chintamani Mande and Mrs. Sutapa Banerjee, for five-year terms. Additionally, the company seeks approval for Non-Executive Director remuneration capped at 1% of net profits.
முக்கிய அம்சங்கள்
AGM scheduled for July 2, 2026, with the e-voting period running from June 29 to July 1, 2026.Ratification of 1st interim dividend (₹0.80) and 2nd interim dividend (₹1.20) per share for FY 2025-26.Proposed appointment of Dr. Shekhar Chintamani Mande and Mrs. Sutapa Banerjee as Independent Directors for a 5-year term.Approval sought for Non-Executive Director remuneration aggregating to a maximum of 1% of annual net profits.Re-appointment of retiring directors Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava.
👀 கவனிக்க வேண்டியவை
Investors should participate in the e-voting process starting June 29 to exercise their rights on director appointments and remuneration policies. Since the dividends are ratifications of previously paid amounts, no immediate impact on cash flow is expected.
Laurus Labs Joins Dow Jones Best-in-Class World Index; ESG Score Rises to 81
Laurus Labs has achieved a significant milestone by being included in the Dow Jones Best-in-Class (DJ BIC) World Index for the first time. This inclusion is driven by a substantial improvement in the company's S&P Global Corporate Sustainability Assessment (CSA) score, which rose to 81 out of 100 from 71 in the previous year. The recognition highlights the company's commitment to ESG parameters and places it among global leaders in the pharmaceutical sector. This development is expected to enhance the company's credibility and attractiveness to global institutional investors and ESG-focused funds.
முக்கிய அம்சங்கள்
First-time inclusion in the prestigious Dow Jones Best-in-Class (DJ BIC) World Index.S&P Global CSA score improved significantly to 81/100, up from 71/100 in the previous year.Previously featured in the S&P Global Sustainability Yearbook 2026 for strong ESG performance.The inclusion recognizes the company's commitment to sustainable and ethical corporate governance practices.
👀 கவனிக்க வேண்டியவை
Investors should consider this a positive qualitative development that strengthens the company's institutional appeal. This may lead to increased interest from ESG-mandated global funds, potentially supporting the stock's long-term valuation.
Laurus Labs FY26 Revenue Up 23% to INR 6,813 Cr; PAT Surges 148% on CDMO Growth
Laurus Labs delivered a robust FY26 performance with total revenue reaching INR 6,813 crores, driven by a 38% growth in the small molecule CDMO segment. The company's EBITDA margin expanded significantly by 6.7 percentage points to 26.8%, while Profit After Tax (PAT) surged by 148% to INR 889 crores. Strategic diversification is evident as the CDMO share rose to over 30% of total revenue, reducing dependence on the ARV segment to 41%. The company continues its aggressive expansion with a full-year capex of INR 1,070 crores focused on high-growth modalities like peptides and fermentation.
முக்கிய அம்சங்கள்
FY26 Revenue grew 23% YoY to INR 6,813 crores, with Q4 EBITDA margins reaching a high of 28.9%.Small molecule CDMO business crossed the INR 2,000 crore mark, growing 38% driven by late-stage pipeline programs.Full-year PAT increased by 148% to INR 889 crores, supported by strong operating leverage and a better product mix.Invested INR 1,070 crores in capex during FY26, with over 75% dedicated to expanding CDMO and CMO capabilities.Financial health improved with Net Debt to EBITDA falling to 1.25x from 2.3x in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful transition toward a CDMO-heavy model and the upcoming commissioning of the Vizag fermentation and Unit 7 facilities. The significant improvement in debt-to-EBITDA levels provides a comfortable cushion for ongoing large-scale capital expenditure.
Laurus Labs Appoints Two New Independent Directors for 5-Year Terms Starting July 2026
Laurus Labs has announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for five-year terms starting July 02, 2026. Dr. Mande is a distinguished scientist and former Director General of CSIR, while Ms. Banerjee brings over 30 years of experience in global financial services and wealth management. These appointments coincide with the retirement of Mrs. Aruna Bhinge, who will complete her second term on July 06, 2026. The addition of high-caliber experts from scientific and financial domains is expected to strengthen the board's strategic oversight.
முக்கிய அம்சங்கள்
Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term effective July 02, 2026.Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term effective July 02, 2026.Mrs. Aruna Bhinge to retire on July 06, 2026, after completing two full terms as an Independent Director.New directors bring expertise from the Council of Scientific and Industrial Research (CSIR) and major banks like ANZ Grindlays and ABN AMRO.
👀 கவனிக்க வேண்டியவை
Investors should view these appointments as a positive step toward enhancing corporate governance and technical expertise at the board level. No immediate action is required as these changes are part of routine board succession planning.
Laurus Labs to Invest EUR 9.8 Million in KRKA Pharma JV for New Manufacturing Facility
Laurus Labs has approved an additional investment of up to EUR 9.8 million in its joint venture, KRKA Pharma Private Limited. The Slovenian co-venturer, KRKA d.d., will also invest approximately EUR 10.2 million, maintaining the existing 49:51 shareholding ratio. These funds are specifically designated for capital expenditure to establish a new manufacturing facility in India. The JV, incorporated in 2024, is currently providing R&D services and reported a turnover of INR 10.47 million in FY26.
முக்கிய அம்சங்கள்
Laurus Labs to invest up to EUR 9.8 million (approx. INR 88-90 Cr) in KRKA Pharma JVCo-venturer KRKA d.d. Slovenia to invest EUR 10.2 million to maintain 51% stakeInvestment proceeds will be used for setting up a new manufacturing facilityLaurus Labs will maintain its 49% equity stake in the joint ventureThe investment is scheduled to be completed during the financial year 2026-27
👀 கவனிக்க வேண்டியவை
This expansion signals a commitment to long-term growth and capacity building in partnership with a global pharma player. Investors should view this as a positive strategic move, though the financial benefits will only materialize once the new facility becomes operational.
Laurus Labs Appoints Dr. Shekhar Mande and Ms. Sutapa Banerjee as Independent Directors
Laurus Labs has announced the appointment of two high-profile Independent Directors, Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee, for five-year terms starting July 2, 2026. Dr. Mande is a renowned scientist and former Director General of CSIR, while Ms. Banerjee is a veteran in financial services and wealth management. These appointments follow the scheduled retirement of Mrs. Aruna Bhinge on July 6, 2026, after a 10-year tenure. The inclusion of such experts is expected to bolster the company's strategic oversight in R&D and financial governance.
முக்கிய அம்சங்கள்
Dr. Shekhar Chintamani Mande appointed as Independent Director for a 5-year term starting July 2, 2026.Ms. Sutapa Banerjee appointed as Independent Director for a 5-year term starting July 2, 2026.Mrs. Aruna Bhinge to retire on July 6, 2026, after completing two consecutive 5-year terms.New directors bring significant expertise from CSIR (scientific research) and top-tier banking/wealth management.
👀 கவனிக்க வேண்டியவை
The addition of a top scientist and a finance veteran to the board strengthens corporate governance and strategic depth. Investors should view this as a positive development for the company's long-term oversight.
Laurus Labs Declares 2nd Interim Dividend of Rs 1.20 per Share; Record Date May 08
Laurus Labs has approved a second interim dividend of Rs 1.20 per equity share for the financial year 2025-26, which represents 60% of the face value of Rs 2. The company has designated May 08, 2026, as the record date to identify eligible shareholders for this distribution. The dividend is scheduled to be paid to shareholders on or after May 20, 2026. This move reflects the company's continued commitment to returning value to its shareholders during the fiscal year.
முக்கிய அம்சங்கள்
Approved 2nd interim dividend of Rs 1.20 per equity share for FY 2025-26Dividend payout represents 60% of the face value of Rs 2 per shareRecord date for determining shareholder eligibility is fixed as May 08, 2026Dividend payment will be processed on or after May 20, 2026
👀 கவனிக்க வேண்டியவை
Investors looking to benefit from this dividend should ensure they hold the stock before the ex-dividend date, which is typically one business day before the May 08 record date. Long-term investors should monitor the company's overall payout ratio and earnings growth to assess dividend sustainability.
Laurus Labs FY26 Net Profit Jumps 148% to ₹889 Cr; EBITDA Margins Expand to 26.8%
Laurus Labs reported a robust performance for FY26, with annual revenue growing 23% to ₹6,813 crore and net profit surging 148% to ₹889 crore. The growth was primarily driven by a 38% increase in the CDMO Small Molecules segment and an 18% rise in the Affordable Medicines division. EBITDA margins saw a significant expansion of 670 basis points to 26.8%, aided by a favorable product mix and operating leverage. The company also declared a second interim dividend of ₹1.2 per share and signaled increased CAPEX intensity for FY27-28 to support new technology platforms.
முக்கிய அம்சங்கள்
Full-year FY26 Net Profit grew 148% YoY to ₹889 crore, with Q4 profit rising 19% to ₹279 crore.EBITDA margins improved significantly by 6.7% points to 26.8% for FY26, supported by a 60.4% gross margin.CDMO Small Molecules segment revenue grew 38% in FY26 to ₹1,896 crore, backed by 125+ active projects.FY26 CAPEX stood at 16% of sales, with planned increases for FY27-28 in Peptides and Gene therapy.Declared a second interim dividend of ₹1.2 per share during the fourth quarter.
👀 கவனிக்க வேண்டியவை
Investors should note the significant margin recovery and the scaling CDMO business which is diversifying revenue away from the volatile ARV segment. The aggressive CAPEX plan for high-value technologies like ADCs and Peptides positions the company for long-term growth despite short-term capital intensity.
Laurus Labs FY26 Net Profit Surges 151% to ₹890 Cr; Declares ₹1.20 Interim Dividend
Laurus Labs reported a robust financial performance for the fiscal year ended March 31, 2026, with annual consolidated revenue growing 23% to ₹6,812.90 crore. The company's net profit for FY26 saw a massive jump of 151%, reaching ₹889.85 crore compared to ₹354.41 crore in the previous year. For the fourth quarter alone, net profit stood at ₹281.91 crore, nearly a four-fold increase from the ₹73.45 crore reported in Q4 FY25. Additionally, the board has approved a second interim dividend of ₹1.20 per share, rewarding shareholders for the strong performance.
முக்கிய அம்சங்கள்
Annual Consolidated Revenue increased by 22.7% YoY to ₹6,812.90 crore in FY26.Full-year Net Profit grew by 151% YoY to ₹889.85 crore from ₹354.41 crore in FY25.Q4 FY26 Net Profit rose to ₹281.91 crore, a significant jump from ₹73.45 crore in the year-ago quarter.Declared a 2nd interim dividend of ₹1.20 per share (60% of face value) with a record date of May 08, 2026.Earnings Per Share (EPS) for FY26 improved significantly to ₹16.47 from ₹6.65 in the previous fiscal.
👀 கவனிக்க வேண்டியவை
The significant turnaround in profitability and strong revenue growth indicate that the company's expansion and operational strategies are yielding high returns. Investors should consider holding the stock as the company demonstrates strong operational leverage and consistent dividend payouts.
Laurus Labs Clarifies Filing Lapses; Reports Strong Q2 FY26 Net Profit of ₹194.49 Cr
Laurus Labs has responded to NSE's clarification request regarding technical discrepancies in its September 2025 financial filings, attributing them to portal glitches and inadvertent selection errors. Despite these procedural lapses, the company's financial performance for Q2 FY26 shows a significant recovery, with revenue growing to ₹1,653.47 crore from ₹1,223.70 crore YoY. Net profit surged to ₹194.49 crore compared to just ₹19.95 crore in the previous year's corresponding quarter. The company has also confirmed an interim dividend of ₹0.80 per share.
முக்கிய அம்சங்கள்
Revenue from operations increased 35% YoY to ₹1,653.47 crore for the quarter ended September 30, 2025Net profit witnessed a massive jump to ₹194.49 crore in Q2 FY26 from ₹19.95 crore in Q2 FY25Board approved an interim dividend of ₹0.80 per equity share (40% of face value) for FY 2025-26Company rectified XBRL filing discrepancies and submitted revised machine-readable financial resultsH1 FY26 total income reached ₹3,260.43 crore, a significant rise from ₹2,425.72 crore in H1 FY25
👀 கவனிக்க வேண்டியவை
Investors should view the regulatory clarification as a resolution of minor procedural issues. The core focus remains on the company's strong earnings turnaround and significant profit growth, which supports a positive long-term outlook.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
